| Title: | Analysis of genotoxic N-nitrosamines in active pharmaceutical ingredients and market authorized products in low abundance by means of liquid chromatography - tandem mass spectrometry |
| Address: | "Federal Institute for Drugs and Medical Devices, Bonn, Germany. Electronic address: matthias.vogel@bfarm.de. Federal Institute for Drugs and Medical Devices, Bonn, Germany" |
| DOI: | 10.1016/j.jpba.2022.114910 |
| ISSN/ISBN: | 1873-264X (Electronic) 0731-7085 (Linking) |
| Abstract: | "In 2018, high levels of the IARC class IIA carcinogen N-nitrosodimethylamine (NDMA) were analytically verified in the active pharmaceutical ingredient (API) valsartan, resulting in extensive regulatory action on angiotensin-II-receptor antagonists and recall of finished drug products by the pharmaceutical industry to ensure patient safety. The root cause of contamination was the unintended reaction of common reagents utilized during drug synthesis. This lead to serious effects on drug quality and immediate regulatory action. Thus, routine analysis of drug product contents are inevitable and necessitate thoroughly performed work up procedures of the product as well as adequate validated analytical methods. The nature of N-nitrosamines (NA), ranging from small, semi-volatile compounds up to highly polar molecules, effort sophisticated requirements in terms of instrumental analysis. Up today, gas as well as liquid chromatographic devices coupled to mass spectrometers are the most widespread systems for analysis. Gas chromatographic - mass spectrometric (GC-MS) systems, obviously superior towards liquid chromatography - mass spectrometry (LC-MS) for detecting small volatile compounds like NDMA, reach their limits for broadly designed studies including polar or acidic NA. In this study, a complementary and highly sensitive approach by means of liquid chromatography - tandem mass spectrometry (LC-MS/MS) is presented, including detection of 13 NA deduced from major classes of secondary amines. Thereby, the fully validated approach was performed in accordance to ICH and European Medicines Agency (EMA) guidelines. Quantitative proof-of-concept measurements with various APIs and market authorized tablets as representative drug formulations conclude applicability for further presumably contaminated substances. The approach employs organic or inorganic extraction steps with solid phase extraction (SPE). The limit of detection for the most prominent NA, NDMA and N-diethylnitrosamine (NDEA), were both 0.025 parts-per-billion (ppb) per matrix, respectively" |
| Keywords: | "Chromatography, Liquid/*methods DNA Damage Dimethylnitrosamine/analysis/toxicity Drug Contamination/*prevention & control Humans Nitrosamines/*analysis/toxicity Pharmaceutical Preparations/*chemistry/standards Tandem Mass Spectrometry/*methods Analysis Li;" |
| Notes: | "MedlineVogel, Matthias Norwig, Jochen eng England 2022/07/03 J Pharm Biomed Anal. 2022 Sep 20; 219:114910. doi: 10.1016/j.jpba.2022.114910. Epub 2022 Jun 26" |
